Tumor infiltrating lymphocyte grade as prognostic factor of recurrence in molecular subtypes of breast cancer (triple negative and Her2)

Narrative Review

Additional Files

Published

2022-04-07

How to Cite

Yoncón Romero, R., & Ochoa Alarcón, G. (2022). Tumor infiltrating lymphocyte grade as prognostic factor of recurrence in molecular subtypes of breast cancer (triple negative and Her2): Narrative Review. Oncology Journal (Ecuador), 32(1), 71–85. https://doi.org/10.33821/596

Issue

Vol. 32 No. 1 (2022): April- July

Section

Review Articles

License

Copyright (c) 2022 Ricardo Yoncón Romero, Grecia Ochoa Alarcón

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Crossref
Scopus
Google Scholar
Europe PMC

Authors

DOI:

https://doi.org/10.33821/596

Keywords:

Breast Neoplasms, Lymphocytes, Tumor-Infiltrating, Triple Negative Breast Neoplasms, Receptor, ErbB-2

Abstract

Breast cancer is a common disease affecting women, with significant health-related adverse effects. Tumor-infiltrating lymphocytes (TILs) are recognized as manifestations of the host's antitumor immunity. The following study reviews and summarizes published reports on the effectiveness of high levels of tumor-infiltrating lymphocytes on the prognosis of triple-negative and HER2-enriched breast cancer molecular subtypes. Studies and reviews in English from PubMed were included. A higher percentage of tumor-infiltrating lymphocytes is associated with a better prognosis and survival rate of triple-negative and HER2 -enriched breast cancer. Consequently, such histological markers should be routinely used in the microscopic analysis of breast biopsies.

Downloads

Download data is not yet available.

Most read articles by the same author(s)